ArticleDiscover oncology2025
VDAC1 as prognostic marker and therapeutic target in lung adenocarcinoma: a study integrating bioinformatics and experimental validation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundResearch on the expression and molecular mechanisms of voltage-dependent anion channels (VDACs) in lung adenocarcinoma (LUAD) remains limited. MATERIALS AND
methodsMultiple datasets were utilized to analyze VDACs expression in LUAD and investigate the clinical significance of VDACs-associated genes and signaling pathways. The database analysis results were further validated through cellular and animal experiments.
resultsThe expression levels of VDAC1 and VDAC2 increase with advancing tumor stage. Subsequent survival analysis revealed that elevated mRNA expression of VDAC1 (HR = 1.6, log-rank P = 0.0015), VDAC2 (HR = 1.5, log-rank P = 0.0088), and VDAC3 (HR = 1.7, log-rank P = 0.0026) was significantly associated with shorter overall survival in LUAD patients. The VDACs-based prognostic signature holds significant value for risk stratification, with VDAC1 demonstrating the poorest prognostic impact. We demonstrated that both in vitro and in vivo experiments consistently showed that the combination of trametinib with VBIT-12 markedly suppresses tumor growth.
conclusionThis study integrates bioinformatic insights with experimental validation to clarify the clinical significance and therapeutic potential of VDACs in LUAD, providing a valuable foundation for prognosis assessment and targeted therapy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.